12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral omecamtiv mecarbil: Phase II started

Amgen and Cytokinetics began the double-blind, placebo-controlled, international Phase II COSMIC-HF trial to evaluate oral omecamtiv mecarbil given twice-daily in about 340 patients with heart failure and left ventricular systolic dysfunction. The dose-escalation portion will evaluate 3 oral formulations of 25 and 50...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >